Heart Failure

This week, the top managed care news included a diabetes drug showing positive results in treating heart failure; new lipid guidelines promoting the use of proprotein convertase subtilisin/kexin type 9 inhibitors; and a study finding doctors are more likely to prescribe opioids if they are in a hurry.

Studies on anticoagulants and SGLT2 inhibitors, and guidelines for dyslipidemia and more are anticipated at the meeting.

This week in managed care, the top news included outcomes results in treating heart failure; US prevention experts said more women should get BRCA testing; the American Heart Association offered an advisory on treating high triglycerides with prescription omega-3 fatty acids.

Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.

A discussion with Naeem Khan, MD, vice president of US cardiovascular and metabolic diseases at AstraZeneca, on lessons from the wave of cardiovascular outcomes trials, the new focus on renal outcomes, and what’s next for SGLT2 inhibitors.

The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.

This week, the top managed care news included HHS announcing a finalized rule requiring the disclosure of drug prices in television ads; a report finding high satisfaction with employer health coverage despite the cost; a study finding heart failure is surging among young adults.

Federal prosecutors have reached a $17 million settlement with Acadia after Medicaid fraud allegations; rates of heart failure–related deaths are on the rise among adults between 35 and 64 years old; the FDA has asked manufacturers of sunscreen to review the safety of the chemicals used in their products after a new study found that many of the ingredients in sunscreen may be absorbed into the bloodstream upon use.

For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, 2019, in New Orleans, Louisiana.

More than a decade after an FDA mandate for cardiovascular outcomes trials, cardiologists say insights gained on how 2 new drug classes affect heart failure in diabetes should be used to prevent complications. Several sessions at the 68th Scientific Session of the American College of Cardiology addressed this topic.

A session at the 68th American College of Cardiology Scientific Session continues the ongoing debate whether a CMS reimbursement model has contributed to rising mortality in patients with heart failure.

The 68th American College of Cardiology Scientific Session and Exposition opens with a study that suggests the Apple Watch can detect atrial fibrillation with a reasonable degree of accuracy, giving people an opportunity to get in touch with their doctor before a serious event like a stroke.

In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy—usually an expensive cholesterol drug with a name almost no one could pronounce: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This year, it's tech, and an easy-to-pronounce name: Apple.

A technology update, a new drug approval, and a drug recall due to more impurities.

The analysis discusses the strength of evidence that SGLT2 inhibitors have a class effect in preventing heart failure for patients with diabetes.

People living with HIV are at a greater risk for incident heart failure, with those with higher viral loads and lower CD4+ T cell counts having the greatest risk.

Increased severity of chronic obstructive pulmonary disease (COPD) was associated with an increased risk of mortality and hospitalization in patients with heart failure, according to a recent study published in JAMA Open.

Results presented at the American Heart Association in Chicago provided the strongest evidence to date on what heart failure specialists have discussed for several years now: the possibility that SGLT2 inhibitors might be used to prevent heart failure in patients with type 2 diabetes.

Heart failure hospitalization has been a target for accountable care organizations seeking to find ways to cut costs from the healthcare system. But it remains to be seen how many of the estimated 2 million patients would gain access to the device if it received an expanded indication and payer coverage.

Hospital participants shared how they have utilized technology to enhance care for heart failure patients. Below are some highlights of these resources and initiatives.

In a recent study, researchers looked to determine whether a symptom and psychosocial collaborative care intervention would improve heart failure–specific health status, depression, and symptom burden in patients with heart failure.

Mary Norine Walsh, MD, immediate past president of the American College of Cardiology, discusses the symptoms of peripartum cardiomyopathy, and who is at the highest risk for developing it.

Guidance for primary care physicians prescribing type 2 diabetes therapies comes at an opportune time. A major rift over guidelines for glycemic control has opened between the American College of Physicians, a professional association of internists, and diabetes specialists, including endocrinologists and diabetes educators.

Condition-specific readmissions measures for heart failure, pneumonia, and heart attack may not accurately or fairly reflect hospital quality, according to a study published this week in the Annals of Internal Medicine. The study found significant differences in hospitals' performance when readmissions were assessed for non-Medicare patients and for conditions other than those currently reported, showing that when these additional factors are taken into account, half of the hospitals would be subject to a change in their financial penalty status.

Results from the ODYSSEY Outcomes trial for the PCSK9 inhibitor alirocumab were the top news at the meeting.

The report finds a connection between payment reform and hospital use patterns, but that connection may add to the debate that cardiologists have raised over the effect on patients.

The Patient-Centered Outcomes Institute shared results of 5 recent publications summarizing results from their awardees. The studies included research on a decision aid for patients with heart failure, 2 different approaches to treating mental illness, and addressing chronic pain.

CVD-REAL, the giant study of real-world evidence comparing sodium glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs to treat type 2 diabetes, found a 49% lower risk of all-cause death and a host of other benefits across 6 new, more diverse countries, the study’s lead author told a packed room Sunday at the 67th Scientific Session of the American College of Cardiology in Orlando, Florida.

Healthcare reform pledged to do better for patients with heart failure, creating the incentives and team-based approaches these fragile patients need. In some cases, this has happened, but there have also been unintended consequences, according to a panel appearing Sunday at the 67th Scientific Session of the American College of Cardiology, being held in Orlando, Florida.

Patients who had breast cancer or lymphoma who were treated more than 3 times are more likely to develop congestive heart failure than those who did not have cancer, according to research being presented at the American College of Cardiology’s 67th Annual Scientific Session.